

06 October 2021

ASX Code: MXC

LSE Code: MXC

## Company Presentation October 2021

**MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company')**, a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to provide a copy of its Company Presentation provided to investors.

--Ends--

**Authorised for release by the Executive Chairman, for further information please contact:**

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK Broker – Turner Pope**

Andy Thacker  
+44 203 657 0050  
[info@turnerpope.com](mailto:info@turnerpope.com)

**MGC Pharmaceuticals Ltd**

David Lim  
Company Secretary  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK PR Advisors – Tavistock**

Charles Vivian / Tim Pearson  
+44 207 920 3150  
[mgcpharma@tavistock.co.uk](mailto:mgcpharma@tavistock.co.uk)

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    



# Leading The Way in Plant-based BioPharma

Company Presentation

October 2021

# Disclaimer

The information contained in this presentation and any accompanying oral presentation ("Presentation") is being supplied to you by MGC Pharmaceuticals Limited on behalf of itself and its subsidiaries (together, "MGC"). By accepting this Presentation, you agree to be bound by the following terms.

The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Market Act 2000 (FSMA).

This Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors, and does not contain all information relevant or necessary for an investment decision. The Presentation should be read in conjunction with MGC's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange. This Presentation does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of MGC nor should it or any part of it form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities.

This Presentation is exempt from the general restriction set out in section 21 of FSMA on the communication of financial promotions.

This communication is exempt under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") on the grounds that it is made or directed only to: (a) persons having professional experience in matters relating to investments within the definition of investment professionals in Article 19(5) of the Order; and (b) recipients who are high net worth bodies corporate, unincorporated associations, and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; (all such persons together being referred to as "Relevant Persons"). Persons of any other description, including those that do not have professional experience in matters relating to investments, should not rely or act upon this Presentation, and the controlled investment and controlled activity to which this Presentation relates will only be available to Relevant Persons. If a person is unsure whether they would be classed as a Relevant Person, then they should seek independent legal advice or advice from an investment professional.

## Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists of summarised information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in MGC is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

## No Liability

The information contained in this Presentation has been prepared in good faith by MGC, however no guarantee, representation or warranty, expressed or implied is, or will be made, by any person (including MGC and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, MGC and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including

representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

MGC, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to the general law (whether for negligence, under statute or otherwise), pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

## Forward looking statements

The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute "forward-looking statements" or statements about "future matters", the information reflects MGC's intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, MGC disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.

Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MGC's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in the Presentation constitute a judgment of MGC only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning MGC and its subsidiaries. The forward-looking information contained in the Presentation is expressly qualified by this cautionary statement.

This Presentation must not be distributed, published, reproduced or otherwise made available to any person, in whole or in part, for any purposes whatsoever with addresses the United States, its territories or possessions or in any other jurisdiction outside of Australia or the United Kingdom where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this Presentation in other jurisdictions may be restricted by law, and persons into whose possession this Presentation come should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction and you undertake to indemnify MGC for any loss or damage incurred as a result of your breach of this undertaking.



# Corporate Overview


**MGC Pharmaceuticals Ltd** (ASX/LSE: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

## Issued Capital

Ordinary shares	2,403,495,855
Performance Rights	97,500,000
Unlisted Options & Convertible Notes (\$0.026 - \$0.07)	85,432,986
Convertible Notes	2,100,000

## Shareholder Breakdown




## Capital Structure

ASX/LSE Code	MXC
Market Capitalisation (as at 28 Sept 2021)	~\$139m
Share price (as at 28 Sept 2021)	\$0.058
Cash at Bank (as at 30 June 2021)	~\$5.4m



# Company Mission

“To Build an Innovative, Vertically Integrated bio-pharma company providing Standardised, Affordable PhytoMedicines of the Highest Regulatory Compliance for Targeted global markets and patients”



\* Excludes sales of ArtemiC



# Board of Directors

Highly qualified team with over 15 years of relevant experience



**Roby Zomer**  
Managing Director, CEO & Co.  
Founder

Following 10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, Mr. Zomer joined MGC Pharmaceuticals as Executive Director & CTO, bringing his extensive business contacts, scientific and engineering skillset to bear on ensuring MGC's position as a leader in research and development, as well as ensuring top performance from our global operations.



**Brett Mitchell**  
Executive Chairman & Co.  
Founder

With over 20 years of experience in the founding, financing and management of both private and publicly listed companies, Mr. Mitchell is responsible for the corporate strategy, capital markets and financial management of the company, and is integrally involved in assisting in building a new industry from the ground up in Australia.



**Nativ Segev**  
Non- Executive Director &  
Founder

The founder of MGC Pharma, previously CEO of an Israeli licensed Medical Cannabis company, with over 10 years of experience in the global medical cannabis industry and over 15 years of experience in executive roles. Founded MGC Pharma to expand into the International markets and to raise the quality and viability of medicinal phytocannabinoid products.



**Dr. Stephen Parker**  
Senior Independent Director &  
Chairman of Audit and Board  
Committees

Dr. Parker has over 30 years of corporate finance, directorship, corporate advisory and investment banking experience focused on the pharmaceutical and biotechnology sectors in the UK, Europe and North America, such as the Chairman of Sareum Holdings plc. Dr. Parker is regarded as a leading corporate expert and strategic thinker. He has a reputation for rapid and clear analysis and the ability to translate this analysis into an implemented solution.



**Dr. Ross Walker**  
Non- Executive Director &  
Head of Medical Advisory  
Board

Dr. Walker is a well-known figure in Australian health, as former host of a weekly radio programme and a prominent cardiologist who specialises in echocardiography and preventative cardiology. Dr. Walker has published several books, and lectures both nationally and internationally. His contacts in the medical establishment and beyond allow him to facilitate relationships for MGC and draw positive public attention to the brand.



**Evan Hayes**  
Non- Executive Director

Evan Hayes is a highly experienced Board member and brings over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Mr Hayes graduated with a Master of Science 1st Class Honours (Biotechnology) from the National University of Ireland, Galway and prior to this he finished first in his class from the National University of Ireland, Cork with a Bachelor of Science degree (Honours). Mr Hayes' has also won the Daniel O'Carroll Award for Scientific Research.



# Key Clinical and Operational Management

Leading experts in the medical cannabis space with unparalleled expertise



**Sasha Friedman**  
Chief Operations Officer  
Deputy CEO

12 years of experience in Business Process Design and implementation as a Senior Consultant for Deloitte and a Project Manager in Tel-Aviv-Jaffa municipality. Implementing business solutions in various industries for Enterprise and SMB organisations globally and leading cross-sectional teams



**Dr. Nadya Lisovoder**  
Chief Medical Officer

15 years of domestic and international experience in academic and clinical studies in the pharmaceutical, diagnostic and medical devices industry. Dr. Lisovoder is a regulatory expert and has been a clinical adviser to public biotech companies as well as incubator companies. She has managed clinical trials and has been leading for the Israeli government biomedical research in 7 hospitals in northern Israel in cooperation with universities, international Pharma companies, global CROs and biotech companies.



**Nicole Godresse**  
Global Chief Sales Officer

Nicole has over 20 years' experience in the pharmaceutical/healthcare industry, holding senior roles with major multi-national companies including Eli Lilly, Johnson & Johnson, Schering-Plough, Merck Sharp & Dohme and most recently Tilray. In her most recent roles as General Manager ANZ and Director of Emerging Markets at Tilray, Nicole was Instrumental in launching the first Medical Cannabis brand legally in both Australia and New Zealand, launching one of the first Medical Cannabis clinics in Australia, delivering some of Australia's first government funded cannabis clinical trials and negotiating major exclusive government supply agreements.



**Amir Polak**  
Chief Technology Officer

Mr. Polak is a scientist who, for the last 15 years, has been working within the chemical industry in various fields including pharmaceutical, fuel, bio-fuel and 3D printing, from inception through to release to market. Mr. Polak has an MSc in Chemistry from the Hebrew University (Jerusalem).



**Dr. Jonathan Grunfeld**  
VP Medical Innovation

Certified in Israel, with clinical experience at the MD Anderson Cancer Center, Dr. Grunfeld has spent the last twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cannabis as a treatment for oncological palliative care. Involved in the licensing of care including direct clinical monitoring of circa 5,000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.



**Prof. Uri Kramer**  
Head of Neurology  
Product Development

Prof Kramer has a busy paediatric epilepsy clinic with many patients being treated with cannabis. Prof Kramer has run full scale epilepsy trials with cannabis and brings a wealth of experience in various fields (Paediatric Neurology & Child Development). Additionally, Prof Kramer is a former president of the Israeli League Against Epilepsy.





# Company Highlights

MGC Pharma is a European based, vertically integrated bio-pharma company supplying EU-GMP Phytocannabinoid derived products to patients, with increasing product sales in Australia, NZ, UK, Ireland and Brazil through special access schemes, and new key markets opening in EU and Israel



Since 2018 MGC has held GMP certification for the manufacture of Investigational Medical Products at the Slovenian facility



Three Investigational Medicinal Products (IMPs) in three clinical trials (Phase II and Phase III)



Additional targeted products in development pipeline with wide IP developments and new Phytotherapeutics line



Rapid growing patient base – delivering affordable cannabinoid medicines to patients. Record quarter of sales & revenue in December 2020 quarter



Landmark approval of CannEpil® as a treatment fully covered by insurance for Refractory Epilepsy in Ireland.



Global distribution via extensive network of commercial partners and direct patient access in Australia via acquisition of Medicinal Cannabis Clinics





# Company Strategy

Development and commercialisation of Phytocannabinoid derived products through a vertically integrated, core IP value chain delivering a “Nature to Medicine” business strategy with global distribution capability in place



Genetics



Extraction &  
Isolation into API



Product  
Development



Clinical  
Trials



Distribution



Products

Research &  
Development



# Phytomedicines – Investigational Products



MGC's Phytomedicines are Plant based products proceeding through clinical trials to obtain marketing authorization, which will allow doctors around the world to prescribe a product with accurate claim to treat symptoms

---



These investigational products allow MGC Pharma to provide prescription and OTC medicines at an affordable price point, in comparison to the alternative treatments for untreated conditions

---



These products are the outcome of years of experience and development of our medical team, produced under strict GMP guidelines with QA/QC/QP controls and audits

---



CannEpil® designed as a treatment for Refractory Epilepsy  
CogniCann® designed to improve Dementia and Alzheimer's disease patients quality of life  
CimetrA™ as a treatment to offset the Cytokine Storm and other auto-immune indications

---



Clinical trials and educational symposiums along side training and patient support platform increasing the access of medicines to the market

---



## Clinical R&D – Key Products Trials

Three research areas based on medical experience and large data collections. MGC Pharma has commenced the following clinical trials for three of its key Phytomedicine products CannEpil®, CogniCann® and CimetrA™

### Research Areas

### Key Products

#### Neurology

- Epilepsy
- Dementia
- Cerebral Palsy

#### CannEpil®

Phase IIb Clinical Trial at Schneider Children's Hospital in Israel on the safety and efficacy of **CannEpil®** as an add on treatment in children and adolescents with refractory epilepsy

#### CogniCann®

Phase II Clinical Trial with the University of Notre Dame in Perth, WA to evaluate the potential behavioural benefits **CogniCann®** may have on patients with dementia and Alzheimer's disease

#### Autoimmune

- Anti-Inflammatory
- Anti-Bacterial

#### CimetrA™

**CimetrA™** has been approved for Phase III Clinical Trial starting at Nazareth Hospital, and has begun patient recruitment.

**CimetrA™** does not contain cannabinoids, designed from 4 natural ingredients as a phytomedicine to target viral infections with inflammatory complications.

In December 2020 completed its Phase II Clinical Trail at Nazareth Hospital EMMS, Hillel Yaffe Hospital in Israel and Mahatma Gandhi Mission's Medical College & Hospital in India  
Results from the trial successfully show **CimetrA™** met all its primary and secondary endpoints and statistically significantly improved the clinical recovery of COVID-19 infected patients.



CannEpil® is a Phytocannabinoid derived IMP used as a treatment for Refractory Epilepsy

- Available to prescribe in Australia and UK as an Investigational Medicinal Product (IMP) through early patient access schemes
- **CannEpil®** is an oral oil solution of 20:1 cannabidiol (CBD) and (-)- trans-Δ9-tetrahydrocannabinol (THC)
- Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids
- MGC's first pharmaceutical-grade product targeted for drug resistant (refractory) epilepsy, which accounts for approximately 25% of the people diagnosed with epilepsy
- **Estimated yearly average treatment costs per patient: A\$10,000 – A\$14,000**

## Epilepsy

### Target Market:

- Over 1,900,000 people have epilepsy in Europe (over 480,000 epilepsy patients in UK)
- Over 200,000 epilepsy patients in Australia
- Approximately 25% of people with epilepsy have a drug-resistant (DRA) form
- Estimated population at launch of marketing authorisation is over 200,000 people with DRA (in Europe and Australia)
- Expected time to marketing authorisation **4 years**

The global epilepsy market is expected to be **~A\$12.9bn** by 2023



As originally announced in November 2019, Company Presentation – UK and Australia Roadshow

Source of target market: [Alacrita Market Projections Report](#); Source of estimated average treatment costs (within the EU): [Alacrita Market Projections Report](#); Source of epilepsy medication market: [Medgadget Market Research Future](#)



CogniCann® is MGC Pharma's second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer's disease patients quality of life

- Available to prescribe in Australia as an Investigational Medicinal Product through Early Patient Access Scheme
- **CogniCann®** is a oromucosal spray of cannabidiol (CBD) and (-)- trans-Δ9-tetrahydrocannabinol (THC)
- Produced from two proprietary, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids
- Contains a 3:2 mix of THC (25mg/mL) and CBD (17mg/mL)
- **Estimated yearly average treatment costs per patient : A\$7,800**

## Dementia

### Target Market:

- Over 690,000 people with mild dementia in Europe (over 200,000 mild dementia patients in UK)
- Over 135,000 mild dementia patients in Australia
- Total estimated with mild dementia population 950,000 at marketing authorisation launch (in Europe and Australia)
- Expected time to marketing authorisation **5 years**

The  
global dementia  
medication market  
is expected to exceed  
**~A\$40bn**  
by 2026



As originally announced in November 2019, Company Presentation – UK and Australia Roadshow

Source of target market: [Alacrita Market Projections Report](#); Source of estimated average treatment costs (within the EU): [Alacrita Market Projections Report](#) and Internal Company Evaluation; Source of dementia medication market: [Coherent Market Insights through GlobalNewswire](#)



# CimetrA™

Autoimmune  
Disorders

CimetrA™ is a phytomedicine based on natural ingredients from Artemisinin, Curcumin, and Boswellia serrata, clinically proven to be effective in arresting the Cytokine Storm in COVID-19 patients

- **CimetrA™** uses an enhanced delivery system technology, a platform to deliver natural ingredients more effectively in higher concentrations to the cells, improving bioavailability of natural ingredients
- The Phase II human clinical trial testing **CimetrA™** for treatment of COVID-19 included 50 patients across three hospital sites, Nazareth Hospital EMMS, Hillel Yaffe Hospital in Israel and Mahatma Gandhi Mission's Medical College & Hospital in India
- 33 Patients were in the treatment group and 17 patients were in the placebo group
- **CimetrA™** successfully met all its primary and secondary study endpoints (100% of patients in the treatment group), and all FDA requirements for diversity of patients
- None of the patients in the treatment group required additional oxygen, mechanical ventilation or admission to intensive care

## Target Market:

- The entire world is currently affected by COVID-19 and seeking solutions
- Success of the ArtemiC food supplement formulation suggests an immediate market for CimetrA™
- Expected time to fast tracked marketing authorisation less than one year

CimetrA™ is currently  
in Phase III clinical trial





One Primary Formulation  
Two Product Lines  
Two Revenue Streams  
Capturing the Food Supplement and  
Pharmaceutical markets

• CimetrA™

CimetrA™ is a phytomedicine, defined as a Investigational Medical Product which has clinically proven to be effective in arresting the Cytokine Storm in COVID-19 patients . Currently in Phase III trials.



Currently targeted for  
Central Market Authorization  
**2021**  
With multiple possible  
offlabel indications  
to be researched.



• ArtemiC™

ArtemiC™ is a suite of nutritional supplement products supported by clinical testing with an impact on enhancing the immune system and providing increased ability to fight off potential systemic impacts of currently prevalent viruses. Currently available on the market.



Currently on the market  
Generating significant revenue  
Increased capacity  
for manufacture  
available.



# Drug Delivery Technology


Smart nanostructured materials for drug delivery

## Nano-emulsion, Nano particles & Core-shell microcapsules

MGC is currently conducting research development on smart nanostructured materials to deliver drugs to the target sites with reduced dosage frequency and in a controlled manner, to mitigate the side effects experienced with traditional therapies.

In particular, to resolve the main critical issues encountered with conventional pharmaceutical treatments with the following:

- Specific distribution of the API
- Controllable release of the API
- High bioavailability



 **GraftBio™** SNEDDS Technology



## R&D – Preclinical

Developing medicines that leverage its proprietary medical cannabis formula through clinical trials in Israel, Europe and Australia. Enable future medical product sales across the EU, Australia and other geographies, following the legal and regulatory approvals

### Neurological

CepaCann Oral Spray to treat Cerebral Palsy

Preclinical in process

### Oncological & Cancer Side Effects

Tetrinol Treatment of Anorexia Cachexia in Cancer Patients

Preclinical in process

MXOT01GB01 Treatment of Glioblastoma (NIB Slovenia)

Preclinical in process, Phase I planned H2 2021

MXOT02ME01 Treatment of Melanoma Cancer (RMIT/CannaHub, Aus)

Preclinical in process

MXOT03PC01 Treatment of Prostate Cancer (RMIT/CannaHub, Aus)

Preclinical in process


### Autoimmune Disease – Inflammatory

InCann BiActive Capsule to treat Crohn's and IBS (RMIT/CannaHub, Aus)

Preclinical in process, Phase I planned H2 2021

TopiCann Topical treatment of Eczema and inflamed skin (Slovenia, EU)

Study Results: 70% Reduction in 4 weeks




# Strategic Partnership with RMIT and Hebrew University

MGC Pharma, RMIT & HUJI have developed the CannaHub, a digital research hub for the application of Phytocannabinoid derived medicines including the International Library of Cannabinoids (ILC)

CannaHub was recently granted an EU REDI grant funding three doctoral students for three years, on areas of research, guided by MGC, taking place at the partner institutions



CannaHub provides an interface connecting doctors and patients with clinical research and information on cannabinoid sequences and their potential treatments



## International Library Of Cannabinoids

- ILC is the World's first library of cannabis medicine where details of medical cannabis clinical research, cannabinoid sequences and their treatments can be found
- ILC will collect data from diverse clinical studies, academic publications, patient feedback as well as diverse cannabinoid strains
- Collected and analysed data from the ILC will assist and enhance the work of doctors and researchers, and improve industry efficacy estimates of cannabinoid treatment of various disorders
- ILC could be utilised for the design and implementation of clinical trials via its mobile and web-based applications



# Manufacturing, Distribution and Patient Access





# EU-GMP Manufacturing Facilities



**SLOVENIA:** EU-GMP certified facility capacity to manufacture up to 12,000 prescription products per month – 3 year GMP license granted. Focus on Investigational Medical Products



**MALTA:** CimetrA™ manufacturing facility  
~5 million AUD grant EU Grant, operational October 2021



Combined Ability to manufacture 200,000 units per month under GMP conditions within the EU



# Key Patient Access Agenda

Strategic synergies providing expedited commercial growth



## Relationships on the ground

Strategic Alliance with Australia's leading Epilepsy Association, Epilepsy Action Australia



Creates Doctor & Market awareness

Leading to prescriptions via **Early Patient Access Schemes**



Giving MGC the ability to both wholesale and distribute directly to other clinics, pharmacies & patients to reduce storage and distribution costs, while keeping prices consumer focused.



**Taking ownership of the supply chain all the way to patient.** MGC Pharma completed the acquisition of 100% of the operating telehealth clinic - business assets, data and IP of Medicinal Cannabis Clinics in November 2020, providing an additional operating platform with import and distribution capacity





Thank You For  
Your Time...

mgc pharma



<https://mgcpharma.com.au/>



@mgcpharmaceuticals



@MGC\_Pharma



MGC Pharmaceuticals Ltd

**MGC Pharmaceuticals Ltd**

Roby Zomer +61 8 6382 3390

CEO & Managing Director

[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**UK PR – Tavistock**

Charles Vivian +44 20 7920 3150

[Charles.Vivian@tavistock.co.uk](mailto:Charles.Vivian@tavistock.co.uk)